IARS2 mutations lead to Leigh syndrome with a combined oxidative phosphorylation deficiency

Background Leigh syndrome (LS) is a common mitochondrial disease caused by mutations in both mitochondrial and nuclear genes. Isoleucyl-tRNA synthetase 2 (IARS2) encodes mitochondrial isoleucine-tRNA synthetase, and variants in IARS2 have been reported to cause LS. However, the pathogenic mechanism of IARS2 variants is still unclear. Methods Two unrelated patients, a 4-year-old boy and a 5-year-old boy diagnosed with LS, were recruited, and detailed clinical data were collected. The DNA of the patients and their parents was isolated from the peripheral blood for the identification of pathogenic variants using next-generation sequencing and Sanger sequencing. The ClustalW program, allele frequency analysis databases (gnomAD and ExAc), and pathogenicity prediction databases (Clinvar, Mutation Taster and PolyPhen2) were used to predict the conservation and pathogenicity of the variants. The gene expression level, oxygen consumption rate (OCR), respiratory chain complex activity, cellular adenosine triphosphate (ATP) production, mitochondrial membrane potential (MMP) and mitochondrial reactive oxygen species (ROS) levels were measured in patient-derived lymphocytes and IARS2-knockdown HEK293T cells to evaluate the pathogenicity of the variants. Results We reported 2 unrelated Chinese patients manifested with LS who carried biallelic IARS2 variants (c.1_390del and c.2450G > A from a 4-year-old boy, and c.2090G > A and c.2122G > A from a 5-year-old boy), of which c.1_390del and c.2090G > A were novel. Functional studies revealed that the patient-derived lymphocytes carrying c.1_390del and c.2450G > A variants exhibited impaired mitochondrial function due to severe mitochondrial complexes I and III deficiencies, which was also found in IARS2-knockdown HEK293T cells. The compensatory experiments in vitro cell models confirmed the pathogenicity of IARS2 variants since re-expression of wild-type IARS2 rather than mutant IARS2 could rescue complexes I and III deficiency, oxygen consumption, and cellular ATP content in IARS2 knockdown cells. Conclusion Our results not only expand the gene mutation spectrum of LS, but also reveal for the first time the pathogenic mechanism of IARS2 variants due to a combined deficiency of mitochondrial complexes I and III, which is helpful for the clinical diagnosis of IARS2 mutation-related diseases. Supplementary Information The online version contains supplementary material available at 10.1186/s13023-024-03310-x.


Introduction
Leigh syndrome (LS), also referred to as subacute necrotizing encephalopathy, is the most prevalent mitochondrial disease in childhood and is caused by mutations in both mitochondrial and nuclear genes [1].LS was first reported by Denis Archibald Leigh in 1951 [2], with an estimated prevalence of 1:40,000 [3].Although the incidence rate of LS is low, the clinical symptoms deteriorated rapidly and likely leading to death in infancy [4,5].LS is defined by the degeneration of the central nervous system, including the brain, spinal cord, and optic nerve, which is manifested by the loss of motor skills, appetite, vomiting, irritability, and/or seizures, as well as overall weakness, reduced muscle tone, and lactic acidosis, resulting in cardiac, hepatic, gastrointestinal and renal tubular dysfunction [4].Currently, more than 100 pathogenic genes have been reported to be associated with LS [6].LS is strongly associated with the oxidative phosphorylation system (OXPHOS) [7], and 80% of LS patients exhibit deficiencies of OXPHOS complexes [8].While defects in each of the five OXPHOS complexes have been detected in LS patients, complex I deficiency is the most prevalent, with nearly a third of the LS causative genes linked to complex I deficiency [9,10].Isolated complex IV deficiency and multiple OXPHOS defects are commonly as well [11], providing evidence of biochemical defects to support a clinical diagnosis of LS.
IARS2 encodes a mitochondrial isoleucyl-tRNA synthetase, which is a class I mitochondrial aminoacyl-tRNA synthetase (ARS) [12].There are 37 members of the ARS family, which are associated with cytoplasmic or mitochondrial translation [13].Mutations in genes encoding ARSs can produce highly diverse clinical phenotypes that affect tissues with particularly high metabolic needs [14].As a nuclear-encoded mitochondrial protein, IARS2 needs to be imported from the cytoplasm into the mitochondria, and catalyzes the attachment of an isoleucine residue to a cognate mt-tRNA Ile [15].The patients with IARS2 variants present broad clinical phenotypes including LS, West syndrome and CAGSSS syndrome (cataract, growth hormone deficiency, sensory neuropathy, sensorineural deafness-skeletal dysplasia syndrome) [14][15][16][17][18].To date, 28 cases with IARS2 mutations have been reported worldwide and 25 variants have been discovered [19], 14 of them have shown LS characteristic features [16,17,[19][20][21][22][23].However, the pathogenesis and molecular mechanism of the IARS2 variants still unclear.
In this study, we reported two unrelated patients with LS harboring compound heterozygous IARS2 variants (c.1_390del and c.2450G > A from a 4-year-old boy, and c.2090G > A and c.2122G > A from a 5-year-old boy) by next-generation sequencing.We applied patientderived immortalized lymphocytes and IARS2-knockdown HEK293T cells to explore the pathogenesis of the variants.

Patient recruitment and ethical considerations
The research and all associated procedures were granted approval by Peking University First Hospital (No. 2017-217).Before participating in the study, the patients and their parents provided informed consent.Subsequently, the patients were admitted to the Department of Pediatrics at Peking University First Hospital.

Next-generation sequencing and variants analysis
The next-generation sequencing, including whole exome sequencing (WES), whole genome sequencing (WGS) and mitochondrial genomic sequencing, was performed using the Illumina HiSeq 2000 sequencer (Illumina, USA) [24].The DNA was extracted from the peripheral blood of the patients and their parents.The sequence data was matched to the human reference genome (GRCh38/ hg38).Germline short variants including SNPs, deletions or insertions were assessed using the genome analysis toolkit (GATK) [25].WGS involved high-throughput sequencing of the entire genome and complete variant annotation.WES refered to the capture and enrichment of DNA from the exon regions of the entire genome for high-throughput sequencing.Pathogenic variants can be screened using the following criteria: (a) the inheritance pattern of the variants conforms to Mendel's law of heredity; (b) in the population database, the allele frequency should be less than 1%; (c) pathogenicity analysis predicts that the mutations should be pathogenic or likely pathogenic; (d) there is a correlation between genotype and clinical phenotype.The identified variants were validated through Sanger sequencing.
To verify the variant site of patients, we extracted DNA using a small amount of genomic DNA extraction kit (Beyotime, China) form 1mL peripheral blood of the patients and their parents.The DNA was amplified using Taq Plus Polymerase (Vazyme, China) and then confirmed via Sanger sequencing.The amplification primers used were: Forward primer:

Cell culture conditions
The peripheral blood cells from both patients and their parents were infected with Epstein-Barr virus generated from B95-8 cells (Cell Bank of the Chinese Academy of Sciences, China) to establish immortalized lymphocytes [32].The immortalized lymphocytes were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, USA) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 0.25 µg/mL amphotericin B (Beyotime Biotechnology), and 1% (v/v) penicillin-streptomycin (Beyotime Biotechnology).HEK293T cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were grown in Dulbecco's Modified Eagle Medium (DMEM) medium (Sigma-Aldrich) supplemented with 12% cosmic calf serum (Sigma-Aldrich), 0.25 µg/mL amphotericin B, and 1% (v/v) penicillin-streptomycin.The cells were kept in an incubator (Thermo Fisher Scientific) with a 5% CO 2 atmosphere at a temperature of 37 °C.

Western blotting and blue native PAGE
For western blot, after collected and washed, cells were lysed with RIPA buffer (Cell Signaling Technology, USA) supplemented 1 mM PMSF (Sigma-Aldrich), then incubated the supernatant for 15 min and centrifuged at 12,000 × g for 10 min at 4 °C.The sample concentration was assessed using the Pierce BCA protein assay kit (Thermo Fisher Scientific).Subsequently, the protein sample was denatured with 5× loading buffer for 5 min at 95 °C.The separated samples were transferred onto a 0.22 μm polyvinylidene difluoride membrane (BIO-RAD, USA) after being separated using 10% bis-tris protein gels.The membrane was then blocked with 5% w/v milk and incubated with specific antibodies at room temperature for 1-2 h.Subsequently, the protein signals were visualized using Super-Signal West Pico Chemiluminescent Substrate (BIO-RAD).The primary antibodies used were anti-IARS2 (Proteintech, USA, 1:2000), anti-β-actin (Abcam, UK, 1:2000), anti-TOM70 (Abcam, UK, 1:2000), anti-rabbit IgG, HRP (Cell Signaling Technology, 1:2000), and anti-mouse IgG, HRP (Cell Signaling Technology, 1:2000).

Oxygen consumption rate
We employed the Oxygraph-2k system (Oroboros, Innsbruck, Austria) to assess the oxygen consumption of the cells [29].Almost 1 × 10 7 cells were seeded in cell-culture dish, after the cell density reaches about 80%, collected cells and washed them with PBS.Cells were gently and rapidly added to the machine.Following the measurement of basal respiration, 2 µg/mL oligomycin (Sigma-Aldrich) was administered to assess the ATP-linked mitochondrial respiration of the cells.

Cellular adenosine triphosphate (ATP) detection
The cellular ATP levels were determined using an ATP bioluminescent assay kit (Sigma-Aldrich).Approximately 5 × 10 6 cells were harvested, washed with PBS, and subsequently resuspended in an ATP-extracting solution (100 mM Tris-base, 4 mM EDTA-Na 2 , pH 7.75).Subsequently, the cells were boiled for 90 s, followed by centrifugation at 10,000 × g for 60 s to collect the supernatant.Finally, the supernatant was mixed with Luciferase Assay buffer, and the autofluorescence was detected.The results were corrected with protein concentration.

Mitochondrial reactive oxygen species (ROS) detection
Mitochondrial ROS content was measured by using MitoSOX™ Red reagent (Thermo Fisher Scientific).Approximately 3 × 10 6 cells were seeded in six-well plates.The cells were harvested and washed with PBS upon reaching approximately 80% cell density.Subsequently, the medium was replaced with a working solution containing 5 µM MitoSOX reagent.The cells were incubated at 37 °C for 10 min in the dark, gently collected, and washed with PBS.The fluorescence was determined using an excitation wavelength of 510 nm and an emission wavelength of 580 nm.

Mitochondrial membrane potential (MMP) detection
MMP was measured by using tetramethylrhodamine (Thermo Fisher Scientific).For HEK293T cells, the sixwell plates were seeded with nearly 3 × 10 6 cells.The cells were washed with PBS upon reaching approximately 80% cell density.Then the medium was substituted with DMEM containing 30 nM tetramethylrhodamine. Subsequently, the cells were incubated at 37 °C for 30 min in the dark, gently collected, and washed with PBS three times.The fluorescence was then determined with excitation at 488 nm and emission at 570 nm.As for the immortalized lymphocytes, nearly 3 × 10 6 cells were gathered, and the subsequent processes were the same as those for HEK293T cells.

Statistical analysis
The quantitative experiments were conducted independently three times.The data were presented as the mean ± standard error of the mean (SEM).Statistical analyses were done using GraphPad Prism 8.0 (USA), and the independent Student's t-test was utilized to calculate the P-values.A P-value of less than 0.05 was considered statistically significant (N.S. for P > 0.05, * for P < 0.05, ** for P < 0.01, *** for P < 0.001).

Patient's clinical features and genetics analysis
Patient 1, a 5-year-old boy, was born in a Chinese family with no family history of hereditary metabolic disease, with weighing 20 Kg, head circumference 52 cm and height 113 cm (Fig. 1A).He was G1P1 with a fullterm normal delivery, and weighed 4000 g at birth.The patient frequently caught colds before the age of one and was admitted to the hospital at one and a half years old.Between the ages of 2 and 3 years, the patient's feet were prone to peeling, and the symptom was relieved after vitamin B treatment.At 3 years and 10 months, the patient was readmitted with a high fever, weakness, and an inability to stand.The brain MRI diagnosed encephalitis.At 4 years, the patient's brain MRI showed bilateral caudate nucleus and putamen nucleus were symmetrically swollen, and high diffusion weighted imaging (DWI) signal.(Fig. 1B) At 4 and a half years old, the patient experienced intermittent convulsions of both upper limbs, head, and face, and electroencephalography showed abnormal brain-wave activity.The patient's brain MRI showed long T1 and T2 signals in the bilateral caudate nucleus and putamen nucleus, bilateral basal ganglia atrophy and brain sulci enlargement.Laboratory examination showed normal blood ammonia level (32 µM, normal range 18-60 µM).Whole exome sequencing (WES) and mitochondrial genomic sequencing were carried out to identify the disease-causing gene mutation.Following filtering with established criteria, two site variants (c.2090G > A and c.2122G > A) in the IARS2 gene were found, and no clinically significant mitochondrial genomic-related variants were observed.Segregation analysis confirmed that c.2090G > A from the patient's mother and c.2122G > A from the patient's father (Fig. 1C).
Patient 2, a 4-year-old boy, was born in a Chinese family with healthy parents (Fig. 1A).He was G3P3 with an abdominal delivery, and weighed 4350 g at birth.The child was admitted to the hospital at one and a half years old, weighing 13 kg, with a head circumference of 46 cm and a height of 73 cm.He couldn't speak and had been diagnosed with growth retardation.It was hard for him to sit stably, and he was unable to walk or eat alone.The patient was readmitted at age 3 and diagnosed with dystonia and neurodevelopmental delays.Laboratory examination showed increased blood lactate (6.24 mM, normal range 0.50-2.20 mM), β-hydroxybutyric acid (1.05 mM, normal range 0.02-0.27mM), and creatine kinase (1854.59U/L, normal range 50-319 U/L).Brain magnetic resonance imaging (MRI) revealed long T1 and T2 signals in the lateral caudate nucleus and putamen, reduced cerebral white matter, bilateral basal ganglia symmetry damage, and cerebral dysplasia (Fig. 1B).He was subsequently diagnosed with LS.After filtering with established criteria, WES and mitochondrial genomic sequencing did not detect potential disease-causing gene mutations.Subsequently, whole genome sequencing (WGS) was performed.Following filtering with established criteria, a novel site variant (c.2450G > A) and a deletion variant with 1 and 2 exons (c.1_390del, NC_000001.11:g.220267444_220269568del) in the IARS2 gene were found, and no clinically significant mitochondrial genomic-related variants were observed.Segregation analysis confirmed that c.2450G > A was from the patient's mother and c.1_390del was from the patient's father (Fig. 1C).As shown in Fig. 1D, heterozygous mutations in IARS2 exon 1 and 2 of the patient were found by CNV-Seq.Quantitative PCR results showed that the mRNA level of IARS2 exon 1 and 2 in the patient and his father were significantly decreased compared with both age-matched controls and the patient's mother.

Pathogenicity analysis
We further investigated the pathogenicity of the above IARS2 variants (c.2450G > A, c.2122G > A and c.2090G > A).Firstly, conservation analysis of amino acid indicated that c.2450G > A (p.R817H), c.2122G > A (p.E708K) and c.2090G > A (p.R697S) were highly conservation among difference species (Fig. 2A).Furthermore, we performed allele frequency analysis of these variants.The allele frequency of c.2122G > A and c.2090G > A in gnomAD was extremely low, with 0.00089 and 0.00048, respectively.The other variants have not been recorded.According to Mutation Taster, the c.2450G > A (p.R817H), c.2122G > A (p.E708K), and c.2090G > A (p.R697S) variants were predicted to be disease-causing.The prediction results of PolyPhen2 also indicated that these variants were pathogenic mutations, with a numerical score of 1.0 for c.2450G > A (p.R817H), 1.0 for c.2122G > A (p.E708K), and 0.935 for c.2090G > A (p.R697S) (Fig. 2B).A score range of 0.0 to 1.0 indicated the likelihood of benign to harmful effects.These results suggested that the c.2450G > A, c.2122G > A and c.2090G > A variants were likely to be disease-causing.

Mitochondrial function was impaired in patient-derived lymphocytes
To determine the pathogenicity of IARS2 variants, we constructed immortalized lymphocytes derived from patient 2. However, due to physical condition of patient 1, we were unable to establish immortalized lymphocytes from this patient.As shown in Fig. 3A, the IARS2 protein level of patient-derived immortalized lymphocytes was significantly decreased compared with age-matched control cells.We further investigated the OXPHOS complexes in patient-derived immortalized lymphocytes, the results indicated that the contents of complexes I and III were decreased by ~ 90% and ~ 50% compared with control cells, respectively (Fig. 3B).Patient-derived immortalized lymphocytes showed a significant reduction in basal respiration and ATP-linked respiration compared to control cells (Fig. 3C).In order to further explore the effect of IARS2 variants on mitochondrial function, we measured the cellular ATP level and MMP content, and results showed that the production of cellular ATP and MMP was decreased compared with control cells (Fig. 3D and E).Altogether, these results indicated that patient-derived immortalized lymphocytes had impaired mitochondrial function.

IARS2 deficiency caused mitochondrial dysfunction
To verify the pathogenicity of IARS2 deficiency, shRNA-mediated IARS2 knockdown was established in HEK293T cells, with an 60% decrease in the expression of IARS2 protein (Fig. 4A).In agreement with patientderived immortalized lymphocytes, the contents of OXPHOS complexes I and III were markedly decreased in IARS2 knockdown cells than that in control cells (Fig. 4B).Basal respiration and ATP-linked respiration were also significantly impaired in IARS2 knockdown cells compared with control cells (Fig. 4C).Furthermore, the production of cellular ATP was notably decreased and the mitochondrial ROS level was increased in IARS2 knockdown cells compared with control cells (Fig. 4D, E).These results collectively indicated that IARS2 was indispensable for the maintenance of mitochondrial function, and IARS2 deficiency caused mitochondrial dysfunction by impairing complexes I and III.

IARS2 variants at c.2090G > A, c.2122G > A and c.2450G > A led to mitochondrial dysfunction
To further verify the pathogenicity of these IARS2 variants, we re-expressed wild-type IARS2 and mutant IARS2 carrying c.2090G > A, c.2122G > A or c.2450G > A variants in cells with IARS2 knockdown.Re-expression of wild-type IARS2 in IARS2 knockdown cells significantly increased the level of IARS2 protein.However, the levels of IARS2 protein in re-expressed mutant IARS2 cells carrying c.2090G > A, c.2122G > A and c.2450G > A were all significantly lower than that in wild-type IARS2 cells (Fig. 5A), suggesting that c.2090G > A, c.2122G > A and c.2450G > A variants could cause IARS2 deficiency.We further tested the OXPHOS complexes and mitochondrial function.As shown in Fig. 5B and C, OXPHOS complexes I and III, basal respiration and ATP-linked

Discussion
In this study, we identified four heterozygous variants of IARS2 (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A) from two unrelated Chinese patients of LS, of which c.1_390del and c.2090G > A were novel.Functional studies showed these IARS2 variants could result in IARS2 deficiency, which in turn led to mitochondrial dysfunction due to a combined deficiency of complexes I and III.Our study revealed that IARS2 was essential for mitochondrial OXPHOS function, particularly in the maintenance of OXPHOS complexes I and III.To the best of our knowledge, this is the first report to elucidate the pathogenesis of IARS2 variants.
Although exons account for less than 2% of the human genome, they contain over 85% of known pathogenic mutations.WES is currently the most widely used DNA sequencing technology in clinical practice due to its costeffectiveness and high sequencing depth.However, WES focuses solely on the protein-coding regions, including exons and adjacent intron/exon boundaries, and is unable to detect large fragment indels.In contrast, WGS analyzes the entire genome, encompassing nearly all exon sequences of genes, as well as intron sequences, intergenic regions, and can simultaneously detect mtDNA variations.Moreover, it can identify genomic structural variations such as large fragment deletions, copy number variations, and other gene structural alterations.If WES and mitochondrial genome sequencing fail to detect potential pathogenic gene mutations, WGS can be utilized for reassessment to uncover possible pathogenic gene mutations.In this study, we reported two unrelated children with LS.For patient 1, compound heterozygous IARS2 variants (c.2090G > A and c.2122G > A) were identified by WES, and no clinically significant mitochondrial genomic-related variants were observed.For patient 2, after filtering with established criteria, WES and mitochondrial genomic sequencing did not detect potential disease-causing gene mutations.Subsequently, whole genome sequencing (WGS) was performed, revealing compound heterozygous IARS2 variants, a deletion variant spanning 1 and 2 exons (c.1_390del), and a site variant c.2450G > A. This demonstrates that WGS has further improved the efficiency of disease diagnosis.
To date, there are 25 reported disease-linked variants have been described in IARS2 gene.Of these, only the IARS2 c.2726 C > T (GenBank Reference: NM_018060.3)and c.2725 C > T (GenBank Reference: NM_018060.3)variants in IARS2 were functionally tested.IARS2 protein level were decreased in patient-derived fibroblasts with c.2726 C > T variant compared with control cells, but there was no significant difference in the contents of OXPHOS complexes between patient and control fibroblasts [16].However, IARS2 protein level and OXPHOS complexes levels did not change in the patient-derived fibroblasts with c.2725 C > T variant compared with control cells [34].In this study, we reported two unrelated patients who presented with LS and had biallelic variants (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A) in IARS2.Among these variants, the variants c.2122G > A and c.2450G > A were previously reported in a patient diagnosed with LS and in a family with two Japanese siblings who exhibited milder symptoms of CAGSSS and West syndrome alongside LS, respectively.However, functional tests had not been conducted in previous studies [16,17].Here, our study revealed that the patient-derived lymphocytes carrying c.1_390del and c.2450G > A variants exhibited decreased IARS2 protein level and impaired mitochondrial function due to the deficiency of OXPHOS complexes I and III contents.We further knockdown IARS2 and found that IARS2 deficiency could cause decreased complexes I and III contents, impaired basal respiration and ATPlinked respiration and reduced cellular ATP production, suggesting that IARS2 deficiency led to mitochondrial dysfunction.To verify the pathogenicity of these IARS2 variants, we re-expressed wild-type IARS2 and mutant IARS2 with c.2450G > A, c.2122G > A or c.2090G > A variants in cells with IARS2 knockdown, respectively.The results showed that IARS2 protein levels were damaged with mutant IARS2, and contents of OXPHOS complex I and III, basal respiration, ATP-linked respiration and cellular ATP production were also impaired.These data suggested that these IARS2 variants were pathogenic and could cause mitochondrial dysfunction due to the decreased contents of mitochondrial OXPHOS complexes I and III.
In summary, we report two unrelated Chinese patients who manifested with LS carrying biallelic IARS2 variants (c.1_390del and c.2450G > A, c.2122G > A and c.2090G > A), and reveal that IARS2 deficiency cause combined complexes I and III deficiencies and mitochondrial dysfunction.Our study further expands the gene mutation spectrum of LS, and uncovers that IARS2 is indispensable for the maintenance of mitochondrial complexes I and III, which provides the pathogenic mechanism and functional evidence of IARS2 as a gene causing mitochondrial diseases and contributes to the clinical diagnosis of IARS2 mutation-related diseases.

Fig. 1
Fig. 1 Family pedigree analysis, brain MRI images and variant analysis of IARS2. A. Pedigree analysis of patient 1 and patient 2 from two unrelated Chinese families.Rectangles indicated males, circles female, solid circle rectangled the affected individuals and probands were pointed out by arrows.B. Brain MRI images of patient 1 and 2. The patient 1 on the left showed lesions in the thalamus, periaqueductal, cerebellum and pons when he was 4 years old.The arrow pointed to the high signal were diseased areas.The patient 2 on the right showed long T1 and T2 signals in the lateral caudate nucleus and putamen, reduced cerebral white matter, bilateral basal ganglia symmetry damage, and cerebral dysplasia.The circled pointed to the symmetrical patchy were diseased areas.C. Sequencing chromatograms of IARS2 in patients and their parents.The arrows indicated the mutation sites.D. Quantitative analysis results of IARS2 in patient 2 and his parents

Fig. 2 Fig. 4 Fig. 3
Fig. 2 Conservative and pathogenicity analysis of IARS2 variants.A. The conservation of amino acid of the mutation sites.B. Bioinformatic analysis of allele frequency and pathogenicity prediction about three variants (c.2450G > A, c.2122G > A and c.2090G > A)

Fig. 5
Fig. 5 IARS2 variants at c.2090G > A, c.2122G > A and c.2450G > A led to mitochondrial dysfunction.A-B.Immunoblot (A) and quantification (B) analysis of IARS2 protein in IARS2 knockdown HEK293T cells with re-expression of wild-type IARS2 or mutant IARS2.β-actin was used as control.C-D.BN-PAGE/ immunoblot (C) and quantification (D) analysis for OXPHOS complexes in IARS2 knockdown HEK293T cells with re-expression of re-expressed wild-type IARS2 or mutant IARS2.TOM70 was used as control.E. Oxygen respiration rate of IARS2 knockdown HEK293T cells with re-expression of wild-type IARS2 or mutant IARS2.Basal, basal respiration; Oligo, ATP-linked mitochondrial respiration of the cells added with 2 µg/mL oligomycin.F. Relative cellular ATP content of with re-expression of wild-type IARS2 or mutant IARS2 carrying c.2090G > A, c.2122G > A or c.2450G > A in IARS2 knockdown HEK293T cells.N.S.P > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001